Lubazodone

DB09196ExperimentalSmall molecule

Lubazodone (YM-992, YM-35,995) is an arylpiperazine antidepressant which was being developed as a treatment for depression and obsessive compulsive disorder, and reached phase II clinical trials, but was discontinued. It... It acts as a serotonin reuptake inhibitor and 5-HT2A receptor antagonist.

Formula / weight: C₁₄H₁₈FNO₂ · 251.301 g/mol (avg)
Code names: YM-35,995 · YM-992

Resolves to

Compound

UNII850TB2B172CAS161178-07-0ChEMBLCHEMBL1080884PubChem157919

Structure

InChIKeyHTODIQZHVCHVGM-JTQLQIEISA-NSMILES[H]N1CCO[C@H](COC2=C3CCCC3=C(F)C=C2)C1

Targets

P31645SLC6A4P28223HTR2A

What you can answer from here — as of September 23, 2026

2Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

2+ReferencesStructured and connected to the statements they support

Which drugs share a target with Lubazodone, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account